aminoguanidine

Aminoguanidine hydrochloride (Hydrazinecarboximidamide) is a diamine oxidase and NO synthase inhibitor, used in the treatment of diabetic nephropathy.

Pimagedine is a prototype therapeutic agent for the prevention of formation of advanced glycation endproducts. Pimagedine reacts rapidly with α,β-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone to prevent the formation of advanced glycation endproducts (AGEs).

Aminoguanidine-13C,15N4 (Pimagedine-13C,15N4) is a carbon-13 and nitrogen-15 labeled form of Aminoguanidine. Aminoguanidine (Pimagedine hydrochloride) functions as an inhibitor of diamine oxidase and nitric oxide synthase. It exhibits dose-dependent inhibitory effects on apoptosis induced by adriamycin and possesses antioxidant properties. This compound is utilized in studies related to diabetic nephropathy.

Aminoguanidine hemisulfate, an inhibitor of nitric oxide synthases (NOS) and reactive oxygen species (ROS), effectively suppresses ANE-induced ROS production in vitro and is utilized in cancer research [1].

G256 (Compound 1) is a guanidinyl hydrazone and can also be considered a Schiff base of aminoguanidine. It exhibits antiarrhythmic activity. G256 is the reduced form of NOH-G256, prepared from rabbit and rat liver homogenates using microsomal enzymes in the presence of NADPH and NADH.

Vogeloside is a furanocoumarin glycoside isolated from Triosteum pinnatifidum. Vogeloside inhibits the production of nitric oxide (NO) in lipopolysaccharide (LPS)-activated macrophages.